Is Moderna Stock a No-Brainer Buy After a Key FDA Win?
Yahoo Finance ·
After a significant slump following the height of the COVID-19 pandemic, Moderna ( MRNA +1.00% ) share prices have ripped higher over the past year, surging nearly 150%. Various factors have driven Moderna's rebound, including regulatory progress on one of its most anticipated products. Yet even as this news, plus additional promising announcements, suggests a further recovery ahead for this pandemic-era favorite, keep in mind how much of this "comeback potential" is already priced into one of the hottest biotech stocks . On June 18, Moderna disclosed how a Food and Drug Administration (FDA) advisory committee voted unanimously that the benefits of its mRNA-based flu vaccine, mRNA-1010, outweigh the risks among patients aged 50 or over. The FDA could approve mRNA-1010 as soon as Aug. 5. The candidate is also currently under regulatory review in Australia, Canada, and the European Union.
DYAX Investor Sentiment
Bullish (Long) 52% · Bearish (Short) 48%
323 participants
Related News
- Should You 'Buy' or 'Sell' Tesla Stock Before July 2
- Everpure gains amid report activist Jana has taken a stake
- Veteran Bank Revamps AMD Stock Price Target for 2027
- Intel Stock Jumps as Wall Street Sees AI's Next Big Winner
- Nvidia, AMD, Intel Lead AI Chip Stock Rally as Wall Street Rebounds
- Why Sandisk Stock Is Skyrocketing Today